Saya kutip artikel kesehatan ini dari Medscape.
Semoga bermanfaat!!
Top Medical News Stories of 2011
Laird Harrison
November 28, 2011 — Concerns about simvastatin, linezolid, methylene blue dye, and “bath salts” all made headlines during 2011. The possibility of cancer from cell phones came into the spotlight as well.
That’s not to say that the news was all bad. The US Food and Drug Administration (FDA) approved a new drug for diabetes, linagliptin.
1. FDA Calls for Simvastatin Limits
The FDA played a role in most of this year’s top news stories, starting with a June 8 recommendation that physicians restrict prescribing high doses of the cholesterol medication simvastatin (Zocor, Merck) because of a risk for muscle damage. The FDA drug safety communication states that physicians should limit using the 80-mg dose of simvastatin unless the patient has already been taking the drug for 12 months and there is no evidence of myopathy.
In addition, the FDA required that the label include the new dosing recommendations, as well as warnings not to use the drug with various medications, including itraconazole (Sporanox, Janssen Pharmaceuticals), ketoconazole (Nizoral, Ortho-McNeil Pharmaceutical), posaconazole (Noxafil, Merck), erythromycin, clarithromycin, telithromycin (Ketek, sanofi-aventis), HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine, and danazol.
In addition, the 10-mg dose should not be exceeded in patients taking amiodarone, verapamil, and diltiazem, and the 20-mg dose should not be exceeded when taken with amlodipine (Norvasc, Pfizer) and ranolazine (Ranexa, Gilead).
2. FDA Warns of Methylene Blue and Linezolid Serotonin Interactions
Then, on July 26, the FDA warned against the use of methylene blue or linezolid with serotonergic drugs. In particular, the FDA said in an October 21 update that clinicians should watch out for interactions with serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors. Continue reading →
-7.965247
112.649865